Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Malathion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.89 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.89 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malathion SCHEMBL3705116 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL27358 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL124812 | 0.94 | ALDH1A1 (1.00) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL21693725 | 0.93 | ALDH1A1 (0.97) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL9253814 | 0.91 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL6737957 | 0.91 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| Malathion SCHEMBL4749884 | 0.91 | ALDH1A1 (0.94) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL5134717 | 0.88 | ALDH1A1 (0.88) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL1691874 | 0.87 | ALDH1A1 (0.85) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 | |
| SCHEMBL1692227 | 0.87 | ALDH1A1 (0.85) | ALDH1A1CYP3A4ALOX15HSD17B10CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670493-B2 | Sexual disorders | JENAPHARM GMBH & CO. KG (DE) | 2003-12-30 | — | — | US | disclosed |
| US-20030064973-A1 | Methods and compositions for treating diseases due to androgen deficiency with glucocorticoid receptor antagonist compounds and new compounds | SCHERING AG (DE) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064973-A1 | Methods and compositions for treating diseases due to androgen deficiency with glucocorticoid receptor antagonist compounds and new compounds | NR5A1, SHBG, CYP17A1 | ALDH1A1 2829/4885CYP3A4 2452/4885ALOX15 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.